Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644551 | 0.84 | HRH3 (0.58) | HRH3 | |
| SCHEMBL3973906 | 0.84 | KDM4E (0.49) | HRH3CSNK2A1 | |
| SCHEMBL2257965 | 0.83 | HRH3 (0.52) | HRH3 | |
| SCHEMBL2815582 | 0.83 | TLR9 (0.48) | HRH3 | |
| SCHEMBL25769675 | 0.82 | CSNK2A1 (0.54) | CSNK2A1 | |
| SCHEMBL15321759 | 0.81 | HRH3 (0.45) | HRH3 | |
| SCHEMBL13211065 | 0.81 | HRH3 (0.47) | HRH3 | |
| SCHEMBL3121093 | 0.81 | CSNK2A1 (0.46) | HRH3CSNK2A1 | |
| SCHEMBL5864782 | 0.81 | HRH3 (0.48) | HRH3CSNK2A1 | |
| SCHEMBL6810821 | 0.80 | HTR2C (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | HRH3 129/4885CSNK2A1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.